Whether infection of cells by individual virions occurs randomly or if there is some form (s) of competition or cooperativity between individual virions remains largely unknown for most virus-cell ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Novartis (NVS) announced positive results from KALUMA, a Phase III study for new malaria treatment KLU156. The novel non-artemisinin antimalarial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback